肺癌筛查项目中胞嘧啶戒烟:意大利RISP试验结果
意大利RISP肺癌筛查试验中,7805名现吸烟者中3548人(45.5%)参与戒烟项目,1375人(38.7%)接受胞嘧啶治疗。胞嘧啶组戒烟率50.1%,单纯咨询组8.1%(p<0.05),调整OR 14.53(95%CI 11.67-18.08)。≥65岁人群疗效与毒性相似,女性不良事件更多。
要点
- 肺癌筛查中提供胞嘧啶戒烟,戒烟率显著高于单纯咨询。
- 胞嘧啶常见不良事件为恶心、失眠和腹部不适,女性更易发生。
- ≥65岁人群疗效与安全性与总体相似。
核心结论
- 在肺癌筛查项目中,胞嘧啶治疗与显著更高的戒烟率相关,且安全性可接受,包括≥65岁成人。
研究设计与样本
- 意大利RISP肺癌筛查试验中,自2022年9月起对所有现吸烟参与者提供戒烟项目,可选胞嘧啶1.5 mg递增递减方案。
- 共入组10191人,7805人有现吸烟史,3548人(45.5%)参与戒烟项目,1375人(38.7%)接受胞嘧啶。
- 主要终点为戒烟项目完成后2周内自报持续戒烟,次要终点包括吸烟量减少、可行性和安全性。
主要发现
- 胞嘧啶组戒烟率50.1%,单纯咨询组8.1%(n=2173),p<0.05,调整OR 14.53(95%CI 11.67-18.08)。
- 胞嘧啶组吸烟量减少比例23.4%,单纯咨询组10.0%,p<0.0001。
- 胞嘧啶使用与更高吸烟暴露(包年、基线呼出气一氧化碳)和戒烟动机相关(均p<0.05)。
- 最常见不良事件为恶心(36.2%)、失眠(19.0%)和腹部不适(18.1%)。
- ≥65岁志愿者(n=428,31.1%)疗效与毒性相似;女性不良事件更多,尤其腹部不适(p<0.05)。
关键数值与推荐
- 胞嘧啶方案为1.5 mg递增递减schedule。
- 戒烟率:胞嘧啶组50.1% vs 单纯咨询组8.1%,调整OR 14.53(95%CI 11.67-18.08)。
- 吸烟量减少:23.4% vs 10.0%,p<0.0001。
- 不良事件发生率:恶心36.2%、失眠19.0%、腹部不适18.1%。
- 胞嘧啶组脱落率15.0%,其中28.0%经历至少一次不良事件。
临床怎么用
- 肺癌筛查中可向现吸烟者提供戒烟项目并可选胞嘧啶治疗。
- ≥65岁成人使用胞嘧啶疗效与安全性相似,可考虑使用。
- 女性使用胞嘧啶时需关注腹部不适等不良事件。
局限性
- 主要终点为自报持续戒烟,非生化验证。
- 胞嘧啶组与单纯咨询组非随机分配,存在选择偏倚。
- ≥65岁亚组样本量有限(n=428)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tobacco cessation support should be offered to all participants with active tobacco use within lung cancer (LC) screening programs. Among the pharmacologic options, cytisine is effective and safe, although data in individuals aged 65 years and older remain limited. METHODS: From September 2022, all participants with active tobacco use enrolled in the Rete Italiana Screening Polmonare (RISP) LC screening trial were offered a smoking cessation program, with optional cytisine treatment (1.5 mg on an escalating and deescalating schedule). The primary end point was self-reported continuous smoking abstinence during the 2-week period after completion of the smoking cessation program, assessed at predefined counseling visits or through telephone follow-up when needed. Secondary end points included cigarette consumption reduction, the feasibility of a cessation program within the Italian health care system, and cytisine safety. RESULTS: Overall, 10,191 participants were enrolled; 7805 had a current smoking history, of whom 3548 (45.5%) pursued a tobacco cessation program and 1375 (38.7%) accepted cytisine treatment. The smoking cessation rate was 50.1% among cytisine users versus 8.1% for those receiving counseling alone (n = 2173) (p <0.05), adjusted OR: 14.53 (95% confidence interval [CI]: 11.67-18.08). The cytisine group reported a greater reduction in cigarette consumption (23.4% versus 10.0%, p <0.0001). Cytisine uptake was associated with greater smoking exposure (pack-years, baseline exhaled carbon monoxide) and motivation for smoking cessation (all p <0.05). The most frequent adverse events (AEs) were nausea (36.2%), insomnia (19.0%), and abdominal discomfort (18.1%). Efficacy and toxicity were similar in volunteers aged 65 years and older (n = 428, 31.1%); women experienced more AEs, particularly abdominal discomfort (p <0.05). Dropouts occurred in 15.0% of cytisine users; 28.0% of these experienced at least one AE. CONCLUSIONS: This is the largest analysis of cytisine use within an LC screening program, providing supportive evidence of its potential effectiveness and safety profile, including in adults aged 65 years and older.
引用
- Cani M, Bafunno D, Caumo F, et al. Cytisine for Smoking Cessation Within a Lung Cancer Screening Program: Results From the Italian RISP Trial. J Thorac Oncol. 2026. PMID: 42409118. doi:10.1016/j.jtho.2026.104071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。